154 related articles for article (PubMed ID: 17235355)
1. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.
Stevenson M; Hale AB; Hale SJ; Green NK; Black G; Fisher KD; Ulbrich K; Fabra A; Seymour LW
Cancer Gene Ther; 2007 Apr; 14(4):335-45. PubMed ID: 17235355
[TBL] [Abstract][Full Text] [Related]
2. SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway.
Freitas VM; Vilas-Boas VF; Pimenta DC; Loureiro V; Juliano MA; Carvalho MR; Pinheiro JJ; Camargo AC; Moriscot AS; Hoffman MP; Jaeger RG
Am J Pathol; 2007 Jul; 171(1):124-38. PubMed ID: 17591960
[TBL] [Abstract][Full Text] [Related]
3. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
Green NK; Morrison J; Hale S; Briggs SS; Stevenson M; Subr V; Ulbrich K; Chandler L; Mautner V; Seymour LW; Fisher KD
J Gene Med; 2008 Mar; 10(3):280-9. PubMed ID: 18214996
[TBL] [Abstract][Full Text] [Related]
4. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.
Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ
J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326
[TBL] [Abstract][Full Text] [Related]
5. Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells.
Stevenson M; Boos E; Herbert C; Hale A; Green N; Lyons M; Chandler L; Ulbrich K; van Rooijen N; Mautner V; Fisher K; Seymour L
Gene Ther; 2006 Feb; 13(4):356-68. PubMed ID: 16355117
[TBL] [Abstract][Full Text] [Related]
6. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.
Fisher KD; Stallwood Y; Green NK; Ulbrich K; Mautner V; Seymour LW
Gene Ther; 2001 Mar; 8(5):341-8. PubMed ID: 11313809
[TBL] [Abstract][Full Text] [Related]
7. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
[TBL] [Abstract][Full Text] [Related]
8. Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5
Davies JA; Marlow G; Uusi-Kerttula HK; Seaton G; Piggott L; Badder LM; Clarkson RWE; Chester JD; Parker AL
Viruses; 2021 May; 13(5):. PubMed ID: 34066836
[TBL] [Abstract][Full Text] [Related]
9. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
Morrison J; Briggs SS; Green N; Fisher K; Subr V; Ulbrich K; Kehoe S; Seymour LW
Mol Ther; 2008 Feb; 16(2):244-51. PubMed ID: 18071336
[TBL] [Abstract][Full Text] [Related]
10. Integrin αvβ3 and disulfide bonds play important roles in NGR-retargeted adenovirus transduction efficiency.
Nestić D; Hozić A; Brkljača Z; Butorac A; Pažur K; Jullienne B; Cindrić M; Ambriović-Ristov A; Benihoud K; Majhen D
Life Sci; 2022 Feb; 291():120116. PubMed ID: 34740576
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.
Pereboeva L; Komarova S; Roth J; Ponnazhagan S; Curiel DT
Gene Ther; 2007 Apr; 14(8):627-37. PubMed ID: 17251987
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.
Ogawara K; Rots MG; Kok RJ; Moorlag HE; Van Loenen AM; Meijer DK; Haisma HJ; Molema G
Hum Gene Ther; 2004 May; 15(5):433-43. PubMed ID: 15144574
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
Morrison J; Briggs SS; Green NK; Thoma C; Fisher KD; Kehoe S; Seymour LW
Hum Gene Ther; 2009 Mar; 20(3):239-51. PubMed ID: 19257852
[TBL] [Abstract][Full Text] [Related]
14. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
15. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob.
Matsui H; Sakurai F; Katayama K; Kurachi S; Tashiro K; Sugio K; Kawabata K; Mizuguchi H
Virus Res; 2011 Jan; 155(1):48-54. PubMed ID: 20801174
[TBL] [Abstract][Full Text] [Related]
16. Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.
Borovjagin AV; Krendelchtchikov A; Ramesh N; Yu DC; Douglas JT; Curiel DT
Cancer Gene Ther; 2005 May; 12(5):475-86. PubMed ID: 15706356
[TBL] [Abstract][Full Text] [Related]
17. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors.
Parker AL; Fisher KD; Oupicky D; Read ML; Nicklin SA; Baker AH; Seymour LW
J Drug Target; 2005 Jan; 13(1):39-51. PubMed ID: 15848953
[TBL] [Abstract][Full Text] [Related]
18. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin.
Sarfati G; Dvir T; Elkabets M; Apte RN; Cohen S
Biomaterials; 2011 Jan; 32(1):152-61. PubMed ID: 20889205
[TBL] [Abstract][Full Text] [Related]
19. Ad5
Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL
Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908
[No Abstract] [Full Text] [Related]
20. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
Kraaij R; van Rijswijk AL; Oomen MH; Haisma HJ; Bangma CH
Prostate; 2005 Feb; 62(3):253-9. PubMed ID: 15389777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
